DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,047,726 | +1.4% | 4,223 | -1.9% | 0.15% | +4.8% |
| Q2 2023 | $1,032,960 | -4.8% | 4,304 | 0.0% | 0.14% | -7.1% |
| Q1 2023 | $1,084,780 | -9.3% | 4,304 | -4.5% | 0.16% | -20.4% |
| Q4 2022 | $1,196,248 | +2.8% | 4,507 | 0.0% | 0.20% | -2.0% |
| Q3 2022 | $1,164,000 | +1.8% | 4,507 | 0.0% | 0.20% | +9.3% |
| Q2 2022 | $1,143,000 | +5342.9% | 4,507 | +6074.0% | 0.18% | +2950.0% |
| Q1 2022 | $21,000 | -98.6% | 73 | -98.4% | 0.01% | -97.2% |
| Q4 2021 | $1,488,000 | +10.3% | 4,522 | +2.1% | 0.21% | +1.9% |
| Q3 2021 | $1,349,000 | +13.5% | 4,431 | 0.0% | 0.21% | +15.0% |
| Q2 2021 | $1,189,000 | +19.3% | 4,431 | 0.0% | 0.18% | +14.6% |
| Q1 2021 | $997,000 | +1.2% | 4,431 | 0.0% | 0.16% | -5.4% |
| Q4 2020 | $985,000 | -0.1% | 4,431 | -3.2% | 0.17% | -13.5% |
| Q3 2020 | $986,000 | +24.8% | 4,577 | +2.5% | 0.19% | +6.7% |
| Q2 2020 | $790,000 | +27.8% | 4,467 | 0.0% | 0.18% | -0.6% |
| Q1 2020 | $618,000 | -9.9% | 4,467 | 0.0% | 0.18% | +24.8% |
| Q4 2019 | $686,000 | +6.4% | 4,467 | 0.0% | 0.14% | -7.6% |
| Q3 2019 | $645,000 | – | 4,467 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |